Every 10-Q that Biofrontera Inc (BFRI) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow BFRI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BFRI filings page.
Biofrontera Inc. reported strong top-line growth but continued losses for the quarter and six months ended June 30, 2026. Net product revenue rose to $12.0 million for the quarter and $22.1 million year-to-date, up from $9.0 million and $17.6 million in 2025, driven by Ameluz sales. Loss from operations narrowed to $0.5 million for the quarter and $4.8 million for six months, with net loss of $0.6 million and $5.4 million, respectively.
Cash used in operations improved to $1.7 million in the first half versus $7.2 million a year earlier, but cash and equivalents declined to $4.7 million, and accumulated deficit reached $133.3 million. Management states that current capital resources are not adequate for 12 months and explicitly discloses substantial doubt about the company’s ability to continue as a going concern, absent new financing or milestone receipts.
Leverage includes $4.6 million of senior secured convertible notes and $0.5 million of warrant liabilities, with significant potential dilution from preferred stock, warrants, options and notes. The October 2025 strategic acquisition of U.S. rights to Ameluz and RhodoLED shifted costs from transfer pricing to a sales-based earnout, resulting in $2.6 million earnout expense in the first half. In May 2026, a U.S. International Trade Commission order prohibited import and sale of RhodoLED XL and Ameluz for use with that device; Biofrontera recorded $0.5 million of remediation cost and a related $0.1 million inventory write-down.
Biofrontera Inc. reported first‑quarter 2026 net product revenue of $10.1M, up 17.4% from the prior year, driven mainly by higher Ameluz unit volumes and a late‑2025 price increase. Despite this growth, the company recorded a net loss of $4.8M, slightly larger than in 2025.
Cash and cash equivalents were $6.3M as of March 31, 2026, with operating cash outflows of about $0.1M in the quarter. Management states that existing capital resources are not adequate for twelve months and discloses substantial doubt about continuing as a going concern without additional financing or improved profitability.
The quarter also reflects a new cost structure from the 2025 strategic transaction with the Biofrontera Group, which replaced a 25% transfer‑pricing model with a lower earnout tied to Ameluz sales. Separately, an International Trade Commission final determination on RhodoLED XL led to a $0.5M remediation charge and restrictions on importing and selling certain lamp components, though the company has appealed elements of the patent dispute and the orders are under Presidential Review.
Biofrontera Inc. (BFRI) reported Q3 2025 results and closed a strategic deal for U.S. rights to Ameluz and RhodoLED. Q3 revenue was $6.988 million versus $9.012 million a year ago, reflecting softer seasonality and lower volumes. For the nine months, revenue was $24.605 million versus $24.762 million. The company posted a Q3 net loss of $6.649 million and a nine‑month net loss of $16.176 million.
Liquidity remains tight. Cash and cash equivalents were $3.417 million at September 30, 2025, and management disclosed substantial doubt about continuing as a going concern. Stockholders’ equity moved to a deficit of $2.581 million from $4.433 million at year‑end 2024.
Strategic actions: on October 20, 2025, Biofrontera completed the acquisition of U.S. rights to Ameluz and RhodoLED with a monthly earnout of 12% of U.S. Ameluz revenue (15% above $65.0 million). Financing included $11.0 million of Series C preferred in two tranches ($8.5 million in July and $2.5 million in October). The company finalized the sale of the Xepi product line on November 6, 2025 and reported regaining Nasdaq compliance in November. Convertible notes outstanding were $4.5 million at quarter‑end with a 10% PIK rate and a $0.78 conversion price.